Methamphetamine

Summary

Methamphetamine (CHEMBL1201201) is an approved small-molecule psychotropic drug (ATC N06BA03); indicated across 4 conditions including attention deficit-hyperactivity disorder and methamphetamine dependence.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06BA03
• Indications: 4 conditions
• Clinical trials: 17
• Chemistry: 149.23 Da · C10H15N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201201
Name	Methamphetamine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	10836
ChEBI	CHEBI:6809
ATC	N06BA03
Molecular formula	C10H15N
Molecular weight	149.23
InChIKey	MYWUZJCMWCOHBA-VIFPVBQESA-N

SMILES: C[C@@H](CC1=CC=CC=C1)NC

IUPAC name: (2S)-N-methyl-1-phenylpropan-2-amine

ChEBI definition: A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.

Pharmacological roles (ChEBI): neurotoxin, psychotropic drug, central nervous system stimulant.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: (s)-phenylmethylaminopropane, J6.362B, Metamfetamine, Metamphetamine, Metanfetamina, Methamphetamine, NSC-25115, methamphetamine, (S)-Methamphetamine, (+)-(S)-Methamphetamine, METHAMPHETAMINE, S(+)Methamphetamine

Parent form; salt/anhydrous children: CHEMBL1200952

Patent coverage: 9,139 distinct patent families (28,681 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Trace amine-associated receptor 1, Sigma non-opioid intracellular receptor 1, Trace amine-associated receptor 1, Synaptic vesicular amine transporter, Trace amine-associated receptor 1, Trace amine-associated receptor 1.

Bioactivity

ChEMBL activities: 15 potent at pChembl ≥ 5 of 16 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q923Y8	7.75	EC50	17.81	nM	CHEMBL_ACT_13895554
Q923Y8	7.16	EC50	70	nM	CHEMBL_ACT_7968719
Q923Y9	6.88	EC50	133.3	nM	CHEMBL_ACT_13895569
Q923Y9	6.7	EC50	201.8	nM	CHEMBL_ACT_13895549
Q923Y8	6.55	EC50	278.9	nM	CHEMBL_ACT_13895564
Q923Y9	6.05	EC50	890	nM	CHEMBL_ACT_7968701
Q923Y8	6.04	EC50	920	nM	CHEMBL_ACT_7968715
TAAR1	5.89	EC50	1300	nM	CHEMBL_ACT_7968733
TAAR1	5.82	EC50	1500	nM	CHEMBL_ACT_7967460
Q923Y8	5.74	EC50	1822	nM	CHEMBL_ACT_13895544
Q923Y9	5.69	EC50	2044	nM	CHEMBL_ACT_13895559
Q01827	5.61	Ki	2460	nM	CHEMBL_ACT_13499625
Q01827	5.61	Ki	2460	nM	CHEMBL_ACT_15640897
Q8HZ64	5.28	EC50	5300	nM	CHEMBL_ACT_7968694
SIGMAR1	5.08	Ki	8320	nM	CHEMBL_ACT_737950

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
attention deficit-hyperactivity disorder	4	MONDO:0007743	EFO:0003888
methamphetamine dependence	2	MONDO:0005419	EFO:0004701
obsessive-compulsive disorder	2	MONDO:0008114	EFO:0004242

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
EARLY_PHASE1	6
PHASE1	5
PHASE2	3
PHASE4	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07584369	PHASE4	NOT_YET_RECRUITING	Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study
NCT03825536	PHASE4	COMPLETED	Effect of Methamphetamine on Residual Latent HIV Disease Study
NCT05783817	PHASE2	RECRUITING	MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)
NCT06721494	PHASE2	RECRUITING	A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine
NCT03226223	PHASE2	COMPLETED	Pharmacogenetics of Naltrexone for Stimulant Abuse
NCT01843205	PHASE1	COMPLETED	Buspirone as a Candidate Medication for Methamphetamine Abuse
NCT03106571	PHASE1	TERMINATED	Study of Pomaglumetad and Methamphetamine
NCT03790618	PHASE1	COMPLETED	Effect of Stimulant Drugs on Social Perception
NCT04178993	PHASE1	COMPLETED	Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
NCT04614584	PHASE1	COMPLETED	Mirtazapine and Methamphetamine Drug-drug Interaction Study
NCT06989853	EARLY_PHASE1	RECRUITING	Methamphetamine and Troriluzole
NCT01967381	EARLY_PHASE1	COMPLETED	Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
NCT02058966	EARLY_PHASE1	COMPLETED	Pilot Study of Entacapone for Methamphetamine Abuse
NCT04642820	EARLY_PHASE1	COMPLETED	Drugs Brain and Behavior (DDP)
NCT05003076	EARLY_PHASE1	COMPLETED	Brain Function and EEG
NCT05379959	EARLY_PHASE1	COMPLETED	Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function
NCT02323048	Not specified	COMPLETED	Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 17 clinical and 47 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).